AI summary · may contain errors
A single intravenous infusion of lonvoguran ziclumeran reduces hereditary angioedema attack rates by 87% compared to placebo in a phase 3 trial.
- 3 cited this week
Moving in New England Journal of Medicine.
Rebuilt
AI summary · may contain errors
A single intravenous infusion of lonvoguran ziclumeran reduces hereditary angioedema attack rates by 87% compared to placebo in a phase 3 trial.
Newest first · last 60 days
AI summary · may contain errors
In LIBREXIA-ACS, milvexian added after acute coronary syndrome did not reduce cardiovascular death, myocardial infarction, or ischemic stroke, and showed no intracranial or fatal bleeding increase.
AI summary · may contain errors
Endosomal PAR 2 signaling amplifies histamine-driven nociceptor sensitization in mouse colonic pain models, producing sustained hyperexcitability linked to IBS-like fecal supernatants.
AI summary · may contain errors
Milvexian added to antiplatelet therapy after acute coronary syndrome does not significantly reduce major adverse cardiovascular events in high-risk patients.
AI summary · may contain errors
A single intravenous infusion of lonvoguran ziclumeran reduces hereditary angioedema attack rates by 87% compared to placebo in a phase 3 trial.
AI summary · may contain errors
A phase 3 trial found that a single dose of lonvoguran ziclumeran, an in vivo CRISPR-Cas9 therapy targeting KLKB1, significantly reduced hereditary angioedema attack rates.
AI summary · may contain errors
FXI-targeting monoclonal antibodies amrecibart and cenvacibart inhibit intrinsic pathway-triggered coagulation without affecting extrinsic pathway in humans and primates.
AI summary · may contain errors
Saccharomyces cerevisiae cells lacking Sky1 show very low vacuolar polyphosphate levels, with the defect worsened by alkaline stress.
Journals this month
Topics moving, week to 17 Nov 2026
By field